Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone
Autore:
Sikiric, P; Seiwerth, S; Grabarevic, Z; Balen, I; Aralica, G; Gjurasin, M; Komericki, L; Perovic, D; Ziger, T; Anic, T; Prkacin, I; Separovic, J; Stancic-Rokotov, D; Lovric-Bencic, M; Mikus, D; Staresinic, M; Aralica, J; DiBaggio, N; Simec, Z; Turkovic, B; Rotkvic, I; Mise, S; Rucman, R; Petek, M; Sebecic, B; Ivasovic, Z; Boban-Blagaic, A; Sjekavica, I;
Indirizzi:
Univ Zagreb, Fac Med, Dept Pharmacol, Zagreb 41000, Croatia Univ Zagreb Zagreb Croatia 41000 , Dept Pharmacol, Zagreb 41000, Croatia Univ Zagreb, Fac Med, Dept Pathol, Zagreb 41000, Croatia Univ Zagreb Zagreb Croatia 41000 Med, Dept Pathol, Zagreb 41000, Croatia
Titolo Testata:
JOURNAL OF PHYSIOLOGY-PARIS
fascicolo: 1-6, volume: 95, anno: 2001,
pagine: 261 - 270
SICI:
0928-4257(200101/12)95:1-6<261:CACLIR>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
RESTRAINT STRESS; ADAPTIVE CYTOPROTECTION; EXPERIMENTAL-MODEL; DOPAMINE AGONISTS; ANTIULCER AGENTS; INDUCED COLITIS; BPC-157; INDOMETHACIN; PEPTIDE; STOMACH;
Keywords:
cysteamine colon lesions; pentadecapeptide BPC 157; gastroduodenal antiulcer agents; remedies for inflammatory bowel disease; cysteamine duodenal lesions; cysteamine colon; duodenum lesion link; extenuation of antiulcer agents protection;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: Sikiric, P Univ Zagreb, Fac Med, Dept Pharmacol, Salata 11,POB 916, Zagreb41000, Croatia Univ Zagreb Salata 11,POB 916 Zagreb Croatia 41000 00, Croatia
Citazione:
P. Sikiric et al., "Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone", J PHYSL-PAR, 95(1-6), 2001, pp. 261-270

Abstract

Recently, we showed cysteamine-duodenal lesions without gastric acid, since they were induced also in gastrectomized rats, as in naive rats, and theywere inhibited by the novel stomach pentadecapeptide BPC 157 as well as standard antiulcer drugs (i.e. cimetidine, ranitidine, omeprazole, bromocriptine, atropine). Therefore, as an advantage of considering cysteamine as a directly acting cytotoxic agent and mentioned agents as direct cytoprotective agents, the present focus was on the ulcerogenic effect of cysteamine andprotective effect of gastroduodenal antiulcer agents outside upper gastrointestinal tract (i.e. in colon). Intrarectal administration of the cysteamine (200 or 400 mg/kg b.w) produced severe colon lesions (i.e. transmural inflammation with serosal involvement) in rats (30 min-72h-experimental period), apparently distinctive from smaller lesions after non-specific irritantenema [diluted HCl solution, pH 3.8 (adjusted to pH of cysteamine solution(pH 3.8)]. All of the tested antiulcer agents were applied simultaneously with cysteamine enema (8 cm from the anus, in a volume of the 1.0 ml/rat) intraperitoneally (i.p.), intragastrically (i.g.) or intrarectally (i.r.). Pentadecapeptide BPC 157 (10 mug or 10 ng/kg b.w.), given in either regimen,previously shown to have, besides others, a particular beneficial activityjust in the intestinal mucosa, inhibited these cysteamine colon lesions (assessed after 30 min, 60 min, 180 min, 24 h, 48 h, 72 h following cysteamine in a dose of either 200 or 400 mg/kg i.r.). Cysteamine-colon lesions werealso attenuated by standard antiulcer agents (mg/kg b.w.), given i.p., i.g., or i.r., such as ranitidine (10), cimetidine (50), omeprazole (10), atropine (10), together with methylprednisolone (1), and sulphasalazine (50, i.r.), assessed 30 min following application of 200 mg of cysteamine. Finally, standard cysteamine duodenal lesions (assessed 24 h after a subcutaneous application of 400 mg/kg of cysteamine) were also attenuated by these agents application (given in the same doses, i.p., 1 h before cysteamine), with only exception to sulphasalazine. Thus, the extended cysteamine specific ulcerogenic effect, cysteamine colon/duodenum lesion-link and an extenuation of agents protection from upper to lower part of gastrointestinal tract (i.e. stomach pentadecapeptide BPC 157, standard antiulcer agents, cimetidine,ranitidine, atropine, omeprazole) and vice versa (remedies for inflammatory bowel disease) evidenced in the present study may be potentially important for both further experimental and clinical research. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 12:29:01